Sugi Predict

Sugi Predict / Compounds / SCHEMBL1753873

SCHEMBL1753873

SCHEMBL1753873

CCCCCNC(=O)C(C)C

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ DPP7 Q9UHL4 2/20 0.60
▸ EPHX1 P07099 8/20 0.58
▸ MMP8 P22894 1/20 0.56
▸ RRM1 P23921 1/20 0.55
▸ CASP2 P42575 1/20 0.52
▸ GNAI3 P08754 1/20 0.51
▸ GNAO1 P09471 1/20 0.51
▸ GNAI1 P63096 1/20 0.51
▸ FNTA P49354 1/20 0.51
▸ FNTB P49356 1/20 0.51
▸ NAAA Q02083 2/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ CYP2D6 P10635 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ KMT2A Q03164 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18896155 0.98 EPHX1 (0.61) DPP7EPHX1MMP8RRM1CASP2
SCHEMBL5059517 0.98 EPHX1 (0.61) DPP7EPHX1MMP8RRM1CASP2
SCHEMBL11035085 0.98 EPHX1 (0.61) DPP7EPHX1MMP8RRM1CASP2
SCHEMBL24072564 0.98 EPHX1 (0.61) DPP7EPHX1MMP8RRM1CASP2
SCHEMBL10248180 0.98 EPHX1 (0.61) DPP7EPHX1MMP8RRM1CASP2
SCHEMBL25454649 0.98 EPHX1 (0.61) DPP7EPHX1MMP8RRM1CASP2
SCHEMBL14076747 0.98 EPHX1 (0.61) DPP7EPHX1MMP8RRM1CASP2
SCHEMBL19910579 0.98 EPHX1 (0.61) DPP7EPHX1MMP8RRM1CASP2
SCHEMBL16410230 0.98 EPHX1 (0.61) DPP7EPHX1MMP8RRM1CASP2
Bromide SCHEMBL29127625 0.94 EPHX1 (0.57) DPP7EPHX1MMP8RRM1CASP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9527042-B2 Separation membrane for water treatment and production method for same TORAY INDUSTRIES, INC. (JP) 2016-12-27 — — US claimed
EP-2671628-A1 SEPARATION MEMBRANE FOR WATER TREATMENT AND PRODUCTION METHOD FOR SAME Toray Industries, Inc. (JP) 2013-12-11 — — EP claimed
US-20130284664-A1 SEPARATION MEMBRANE FOR WATER TREATMENT AND PRODUCTION METHOD FOR SAME TORAY INDUSTRIES, INC. (JP) 2013-10-31 — — US claimed
US-20240226026-A1 BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS ARES CAPITAL CORPORATION, AS AGENT 2024-07-11 — — US disclosed
US-20240067650-A1 MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF LUMIPHORE, INC. 2024-02-29 — — US disclosed
US-20240025878-A1 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-25 — — US disclosed
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 — — US disclosed
US-11807636-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-11-07 — — US disclosed
US-11780935-B2 Mutant antibodies and conjugation thereof PFIZER HEALTHCARE IRELAND (IE) 2023-10-10 — — US disclosed
US-11780935-B2 Mutant antibodies and conjugation thereof PFIZER HEALTHCARE IRELAND (IE) 2023-10-10 — — US disclosed
WO-2023192578-A1 PROTEIN DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-10-05 — — WO disclosed
US-20080177303-A1 Shape memory polymers ROCHESTER, UNIVERSITY OF 2008-07-24 — — US disclosed
US-20080070936-A1 Compounds specific to adenosine A1 receptors and uses thereof OSI PHARMACEUTICALS, INC. 2008-03-20 — — US disclosed
US-7160890-B2 Compounds specific to adenosine A3 receptor and uses thereof OSI PHARMACEUTICALS, INC. (US) 2007-01-09 — — US disclosed
US-5864043-A CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST KARL THOMAE GMBH (DE) 1999-01-26 — — US disclosed
US-5614519-A (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists KARL THOMAE GMBH (DE) 1997-03-25 — — US disclosed
US-5602127-A ADMINISTERING TO TREAT HYPERTENSION KARL THOMAE GMBH (DE) 1997-02-11 — — US disclosed
US-5594003-A HYPOTENSIVE AGENTS DR. KARL THOMAE GMBH (DE) 1997-01-14 — — US disclosed
US-5591762-A HYPOTENSIVE AGENTS DR. KARL THOMAE GMBH (DE) 1997-01-07 — — US disclosed
US-5541229-A ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS DR. KARL THOMAE GMBH (DE) 1996-07-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025878-A1 MDM2 DEGRADERS AND USES THEREOF MDM2, TP53, MDM4 DPP7 816/4885EPHX1 2320/4885MMP8 2465/4885
US-11780935-B2 Mutant antibodies and conjugation thereof IGLV6-57, IGSF11, F13B DPP7 3927/4885EPHX1 944/4885MMP8 4127/4885
US-20240067650-A1 MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF TFRC, CLTC, SLC39A3 DPP7 766/4885EPHX1 4672/4885MMP8 2074/4885
US-20240226026-A1 BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS PLTP, LNPK, PLIN3 DPP7 1738/4885EPHX1 3199/4885MMP8 4321/4885
US-20080070936-A1 Compounds specific to adenosine A1 receptors and uses thereof ADORA1, ADORA2A, ADORA3 DPP7 1185/4885EPHX1 649/4885MMP8 1943/4885
US-11807636-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 DPP7 221/4885EPHX1 1684/4885MMP8 901/4885
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 DPP7 221/4885EPHX1 1684/4885MMP8 901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.